Skip to content
lifestyle.ucconnection.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Arcutis Biotherapeutics, Inc.
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
May 21, 2026
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
April 29, 2026
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
April 22, 2026
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
March 10, 2026
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2026
←
Previous Page
1
2